This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Photo Release -- Hutchinson Technology Announces FDA Clearance Of The InSpectra(TM) StO2 Spot Check

HUTCHINSON, Minn., March 7, 2011 (GLOBE NEWSWIRE) -- Hutchinson Technology Incorporated (Nasdaq:HTCH) today announced that it has received 510(k) clearance of the InSpectra™ StO2 Spot Check from the U.S. Food and Drug Administration. The product, which is targeted for use in emergency and critical care environments, is a cost-effective tool to help rapidly assess tissue perfusion and shock.
InSpectra(TM) StO2 Spot Check
Hutchinson Technology Incorporated's InSpectra(TM) StO2 Spot Check

A photo accompanying this release is available at .

The InSpectra StO2 Spot Check (model 300) consists of a hand-held device, cable, reusable sensor, charging station and rechargeable battery. This product enables clinicians to quickly and cost-effectively identify at-risk patients. Once identified as having low StO2, patients can then be continuously monitored with the InSpectra™ StO2 Tissue Oxygenation Monitor (model 650). These two products help reduce the time to critical actions and identify the endpoints of resuscitation.

"This is an exciting development for the assessment of critically ill patients," said Brahim Ardolic MD, Chair, Department of Emergency Medicine at Staten Island University Hospital (Staten Island, NY). "With Spot Check, we can quickly assess patients at increased risk of adverse effects due to decompensation of their status."

"Multiple clinical studies demonstrate that patients with low StO2 are at risk of poor clinical outcomes and that 20-30% of emergency room and ICU patients have low StO2 even though other vital signs are normal," said Rick Penn, president of Hutchinson Technology's BioMeasurement Division. "In addition, recent research suggests that using StO2 to guide patient treatment results in improved clinical outcomes as well as economic benefits in the form of shorter length of stays in the ICU and the hospital."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs